Regeneron's Arcalyst reduces gout flare-ups in Phase III trial

06/9/2010 | Bloomberg Businessweek

Regeneron Pharmaceuticals' gout drug Arcalyst reduced flare-ups by 80% when administered at 160 milligrams once a week, according to a late-stage trial. The company is banking on the success of Arcalyst and two other experimental drugs in late-stage development to earn as much as $2 billion annually.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC